INmune Bio's ATM offering raises $19M ahead of Phase II results, but disappointing data and dilution signal risks. Read here ...

Cassava Sciences (SAVA) announced that the Company presented a poster at the TSC International Research Conference held June 26-28, 2025 in ...

Data show that simufilam reduced seizure activity in a preclinical mouse model Presentation also highlights favorable human ...

FDA Green-Lights Gilead Sciences’ Groundbreaking HIV Prevention Drug A twice-yearly injection of lenacapavir would offer near-complete protection against the virus, clinical date indicate. More ...

The drug, called Yeztugo from company Gilead Sciences, was approved Wednesday based on data from clinical trials that showed 99.9% of participants who received it remained HIV negative.

About This EventCaris Life Sciences (Nasdaq: CAI), a leading next-generation AI TechBio company and precision medicine pioneer, visits the Nasdaq MarketSite in Times Square.In honor of the ...

Thailand's leadership in the global cassava industry took centre stage at the Global Cassava Sustainability Forum 2025, held today at Pullman Bangkok King Power. Co-hosted by King Mongkut's University ...

ZYUS Life Sciences Corporation (the “Company”) (TSXV: ZYUS), a Canadian-based life sciences company focused on the development and commercialization of novel ...

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 ...

Empty space in conversion projects accounted for roughly 90% of the overall vacancy in Boston's life sciences market as of mid-2024, according to Lincoln Property Co.